Closed Loop Medicine secures strategic partnership with Orient Pharma
Novel Cambridge therapeutics company secures international partnership with Taiwanese Pharma Company.
Closed Loop Medicine (CLM), the Cambridge-based health tech startup that helps doctors and healthcare providers to deliver personalised treatment regimens to patients, has formed its first strategic and commercial partnership with Orient Pharma Co., Ltd., a Taiwan based multinational pharmaceutical, healthcare and consumer products company.
Today CLM announced the signing of a strategic partnership with Orient Pharma, based in Taiwan. This partnership will see CLM and Orient co-develop a sleep product that combines both drug, formulation and digital elements. The agreement includes commercialisation rights for each of the parties in a number of global territories. This deal not only provides CLM with access to novel drug formulation technology but also provides a strategic and commercial route into important international markets.
Closed Loop Medicine (CLM) is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. The company combines proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
Dr Hakim Yadi OBE, CEO and co-founder of CLM said: “We are delighted to sign this partnership with Orient which gains us key proprietary technology for our sleep program and a strategic development partner. However, in addition to signifying our intent to be innovative and develop novel co-therapies of traditional drugs and digital therapeutics, it also signifies our international intent and ambition”.
Calvin Tsai, CEO of Orient Pharma Co. Ltd, said: “Our company is constantly striving towards innovation, we have demonstrated this repeatedly with new product formations and creative product launches in territories across the globe. The next stage in this evolution for Orient is to fully embrace digital. Our partnership with CLM allows us to co-develop a new type of therapy that combines Orient’s expertise in drug formulation with CLM’s approach to precision regimens and digital health”.
About Closed Loop Medicine
Closed Loop Medicine is a Cambridge-based therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. CLM has a development pipeline that integrates Drug + Digital+ Device for the treatment of some of the biggest challenges facing global health systems. For now, CLM is working on treating sleep disorders and hypertension but in the future will be working on other health problems.
By focusing on individual care pathways, CLM can augment proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum for dynamic personalised regimens. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease.
The founders of CLM have a track record of working together and between them have launched many highly successful commercial enterprises including drugs, digital health, diagnostics and devices. The team has full experience of technology development through to market access, reimbursement and uptake.
CLM was founded in 2017. Its HQ is in London, UK.
About Orient PHARMA
Orient PHARMA Co., Ltd. (Orient PHARMA) was established in 2008 and includes a new pharmaceutical plant located at Central Taiwan Science Park in Yunlin County meeting extensive governmental regulations including PIC/S GMP, EU GMP, and FDA 21CFR. In addition, Orient PHARMA has obtained Taiwan FDA PIC/S GMP Certificate in 2011and U.S. FDA CGMP Certificate in 2013. Orient PHARMA’s R&D strategy is focused on researching and developing drugs for the CNS (central nervous system) including anti-psychotic, Alzheimer’s disease, psychostimulants, and anti-Parkinson medicines. Orient PHARMA not only focuses on the development of new drug targets, but also collaborates with global partners in Europe, U.S., and Japan to develop new injections, new formulations, new indications and new products.
For more information, please visit www.oppharma.com